Schering Aktiengesellschaft

Bayer Schering Pharma Ag

Univerzita Palackeho V Olomouci

Ustav Organicke Chemie a Biochemie Av Cr, V.v.i.

Eberhard Karls Universitat Tubingen Medizinische F Akultat

Helmholtz Zentrum Munchen

Ustav Molekularni Genetiky Akademie Ved Cr, V.v.i.

Deutsche Diabetes-Forschungsgesellschaft E.v.—trager Des Deutschen Diabetes-Zentrums Dusseldorf

Helmholtz Zentrum Munchen-deutsches Forschungszentrum Fur Geseundheit Und Umwelt (gmbh)

Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt

Jerzy Adamski

Gabriele Moeller

Walter Elger

Alexander Hillisch

Christian Gege

Birgitt Schneider

Olaf Peters

Wilko Regenhardt

Dominga Deluca

Ulrich Bothe

Marian Hajduch

Thomas Meitinger

Petr Dzubak

Petr Bartunek

David Sedlak

Martin Kotora

Rui Wang-Sattler

Eva Prchalova

Zhongao Yu

H-Erich Wichmann

Hans-Ulrich Haring

Michael Roden

Ondrej Stepanek

Annette Peters

Christine Meisinger

Martin Hrabe De Angelis

Wolfgang Rathmann

Christian Herder

Andrea Rosinus

Thomas Illig

Martin HrabÉ De Angelis

Gabriele Möller

Hans-Ulrich Häring

15&#x3b2;-substituted derivatives of estrone of general formula I wherein R, R, R, R, Rare independently selected from the group consisting of: C-Calkyl, C-Calkoxy, C-Chalogenalkyl, halogen, COORwherein Ris C-Calkyl; H, OH; optionally, R, Rand Rare each formed by a hydrogen atom, while Rand Rtogether form an aryl group, preferably naphthyl, in which the aromatic ring in position C-15 can be mono-, di-, tri-, tetra- and penta-substituted with substituents R-R. Compounds of the invention may be used for diagnosis and possibly also for the treatment of estrogen-dependent diseases.

15&#x3b2;-substituted estrone derivatives as selective inhibitors of 17&#x3b2;-hydroxysteroid-dehydrogenases, method of preparation and use thereof

The present invention relates to a method of identifying a predisposition for developing type 2 diabetes mellitus in a subject, said method comprising the step of assessing in a sample obtained from said subject the amount of one or more metabolite(s) selected from (a) a first group comprising the metabolites glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2, phosphatidylcholine acyl-alkyl C36:3 and isobaric metabolites having the same molecular mass as glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2 or phosphatidylcholine acyl-alkyl C36:3 but different chemical formula; and/or (b) a second group comprising the metabolite acetylcarnitine C2 and an isobaric metabolite having the same molecular weight as acetylcarnitine C2 but different chemical formula; wherein a decrease in the amount of a metabolite selected from said first group or an increase in the amount of a metabolite selected from said second group as compared to the amount of the corresponding metabolite(s) of a control is indicative of a predisposition to develop type 2 diabetes mellitus. Further, the invention relates to a method of identifying a compound capable of preventing type 2 diabetes mellitus and diseases associated therewith or serving as a lead compound for developing a compound capable of preventing type 2 diabetes mellitus and diseases associated therewith and a method of selecting a therapy to prevent type 2 diabetes mellitus. Also, the invention relates to a kit.

Biomarkers for type 2 diabetes

The invention relates to new 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula I in which

2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17&#x3b2;-hydroxy steroid dehydrogenase type 1

The invention relates to new 2-substituted estra-1,3,5(10)-trien-17-ones of formula I as well as their pharmaceutically acceptable salts, their methods of manufacture and use as medicaments for prophylaxis and/or therapy of estrogen-dependent diseases that can be influenced by the inhibition of 17&#x3b2;-hydroxy steroid dehydrogenase type 1.

2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17&#x3b2;-hydroxy steroid dehydrogenase type 1

Growing community of inventors

Munich, Germany

Jerzy Adamski